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than SG, 35.4% vs 17.7% (p<0.05). These complications included myocardial infarction 
2.0/6.25, dysrrhythmia 2.0/10.4%, renal insufficiency 2.5/11.1%, ileus 2.0/18.8% infection 
0.0/6.3%, retroperitoneal bleed 2.0/2.1% and hematoma 9.8/2.1%. 
The American Surgical Association Risk Category (ASA) was equivalent in both groups. 
Mortality and discharge to a skilled nursing facility were more common in the surgical 
population (table). The mean length of stay (day) was 8.0 for surgery and 2.4 for the SG 
9roup. 
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1129-95 Ischemic ECG Response During Dipyr idamole  St ress  
Teat ing Is a Power fu l  P red ic tor  o f  Severe  Coronary  
Ar tery  Disease in Pat ients  With C laud icc t lon  Due to  
Peripheral Arter ia l  D isease 
Dennis G. Caralis. Amjad All, John T. Barron, Rush-Presbyterian-SL uke's Medical 
Center, Chicago, Illinois. 
Type of AGE ASA Aneurysm Discharged Discharged In- Expired or Direct 
treatment (years) Category size (cm) Home* Skilled care hospital Skilled hospital 
facility mortality Care* Cost ($) 
Surgery 69 111=80.0%1V=6.1+1.36 74.9% 19.1% 6.25% 25.0% 8,113 
n= 48 (42-62) 17.5% 
Stent 72 II1= 73.2%1V= 4.9 + 0.92 90.2% 9.7% 0.0% 9.8% 14,661 
Graft (52-88) 24.4% 
n=51 
*P<0.05 
Conclusion: Aortic SG appears to be associated with decreased morbidity, mortality and 
length of hospital stay. Resource utilization defined as the direct hospital cost is higher, 
but there is less utilization of skilled nursing facilities after discharge. 
1129-94 Ef fect  o f  T reatment  on Embollc Events in Patients With 
Severe Thoracic Aortic Atheromas: Interim Data 
Analysis From the NYU Atheroma Group 
Ambika C. Navar, Gregory M. Goodkin, Sunil Mirchandani, Paul A. Tunick, Itzhak 
Kronzon, NYU School of Medicine, New York, New York. 
Background: Severe aortic plaques seen on TEE are associated with a high risk of stroke 
and peripheral embolization. Previous studies have indicated a beneficial effect of war- 
farin, but only in small groups of patients. 
Methods: Since 1988, 1114 pts had thoracic aortic atheromas, at least 5mm or mobile, on 
TEE at our institution. Retrospective information regarding the occurrence of embolic 
events (stroke, TIA, or peripheral) after atheroma diagnosis by TEE, as well as treatment 
with warfarin, antiplatelet drugs (aspirin, ticlopidine, clopidogral), or statins was obtained 
from patient records or direct patient or family contact. Treatment was determined by 
referring physicians and was not randomized. Presented here are interim data from 468 
randomly selected pts. 
Results: Of the 468 pts studied, 179 (38%) received warfarin, 247 (53%) received anti- 
platalet treatment, and 165 (35%) received statin. An embolic event occurred in 97 pts 
(21%) (stroke = 48, TIA = 34, peripheral embolization = 15). Warfarin was being given to 
32 (33%) of these 97 pts, antiplatelet drugs to 48 (49%), and stafin to 18 (19%) at the 
time of their embolic events. Of the 371 pts without emboli, 147 (40%) were receiving 
warfarin, 199 (54%) antiplatelet drugs, and 147 (40%) were on statin. Many pts were on 
multiple drug regimens. The protective effect of statin with respect to embotic events was 
statistically significant (OR 0.35, 95% CI 0.2 - 0.6; P = 0.00009). No significant protective 
effect was found for warfadn (P = 0.22) or antiplatelet drugs (P = 0.45). 
Conclusions: Although these data are from an interim analysis of 42% of our pts, the 
results indicate that there may be a protective benefit of statin, and a lack of a significant 
protective effect of warfarin and antiplatelet drugs in pts with severe thoracic aortic ather- 
omas on TEE. Data from the entire cohort will be more definitive. 
1129-95 Association of Se l f -Repor ted  Le isure  Act iv i ty  and 
Coronary Risk With Carot id  Ar tery  React iv i ty  
Ronald S. McKechnie, Lori Mosca, Melvyn Rubenfira, University of Michigan, Ann Arbor, 
Michigan, Columbia Universi~ New York, New York. 
Background: Regular leisure activity has been shown to reduce cardiovascular risk and 
positively influence risk factors. Vascular reactivity, including carotid and brachial arter- 
ies, is also correlated with coronary risk. We studied the association between self- 
reported, leisure activity and carotid reactivity in response to a sympathetic stressor in 
188 adults. We also evaluated the vascular response with respect to 3 levels of coronary 
risk, Methods: Vascular reactivity was evaluated by percent and absolute change of the 
carotid artery diameter in response to a cold pressor test (CPT) and nitroglycerin. Physi- 
cal activity was assessed by a participant-racall questionnaire. Patients were stratified as 
average-risk (1 abnormal lipid level), high-risk (one coronary risk factor and >/= 1 abnor- 
mal lipid level), or CAD (coronary artery disease-prior myocardial infarction or coronary 
stenosis > 50%). Results: 67% of patients self-reported regular active, mederatsly, or 
extremely active leisure activity versus sedentary or minimally active. Of those patients, 
average-dsk patients increased their diameter in response to CPT by 4.3 +/- 2.7%, which 
was less in the high-risk group (1.4 +/- 1.5%), and vasoconstriction occurred in the CAD 
group (-2.2 +/- 1.5%) (p < 0.001 for comparisons). Among CAD patients, an active life- 
style was associated with significantly less vasoconstriction compared to less active 
patients (-2,2 +/- 1.5% vs. -3.5 +/- 1.6%, p < 0.05). After adjusting for age, BMI, HDL-cho- 
lesterol, triglycerides, baseline diameter and systolic blood pressure, linear regression of 
carotid reactivity in response to CPT in the CAD group maintained the significant associ- 
ation between leisure activity and carotid reactivity (Model R2=0.38, p < 0.05). Conclu- 
sion: In patients self-reporting active levels of leisure activity, this study suggests an 
inverse response of carotid reactivity to CPT in the presence of more coronary risk fac- 
tors, with a significant benefit of leisure activity in patients with CAD. This supports 
national recommendations that regular leisure activity may reduce cardiovascular risk 
potentially through improved endothelial function, specifically in patients with CAD. 
The significance of ST-segment depression in patients undergoing exercise stress test- 
ing has been well investigated; the significance of new ischemic ST depression during 
dipyridamole stress testing has not. This was a cross-sectional observational study of 
100 consecutive men or women (mean age 65 ± 14 years) with intermittent claudication 
of the lower extremities due to peripheral artedal disease (PAD) as indicated by Ankle 
Brachial Index (ABI) <0.8, who also demonstrated new (compared to baseline) ischemic 
ST-segment depression following intravenous dipyridamole infusion (horizontal or 
downsloping ST-segment depression of at least 0.1 mv at 80 ms from the J point on the 
ECG). Dipyridamole was infused using a standard protocol (0.14 mg/kg infused over 4 
min). All patients (100%) had abnormal single photon emission computed tomagraphic 
(SPECT) images consistent with ischemia. Of the 100 patients, 92 agreed to undergo 
coronary angiography. Coronary angiography revealed that all patients had significant 
left main and/or multivessel coronary artery disease (at least 75% luminal stenosis). 
Thus, the appearance of new ST-segment depression during dipyridamole infusion is a 
powerful predictor of severe coronary artery disease in patients with claudication due to 
PAD. 
POSTER SESSION 
1130 Lipid Modifying Drug Therapy: Special 
Patient Populations 
Monday, March 18, 2002, 3:00 p.m.-5:00 p.m. 
Georgia World Congress Center, Hall (3 
Presentation Hour: 3:00 p.m.-4:00 p.m. 
1130-73 S imvastat in  P lus  N iac in  Protect  Against 
Atheroac le ros l s  Progression and Clinical Events in 
Coronary Artery  Disease Pat ients  With Metabo l i c  
Syndrome 
Xue-Qiao Zhao, Josh Morse, Atan Chad, Lloyd Fisher, Alice Dowdy, John J. Albers, Jid 
Frohlich, B. Greg Brown, University of Washington, Seattle, Washington, University of 
British Columbia, Vancouver, British Columbia, Canada. 
Background: Effects of simvastatin plus niacin (SN(+)) on lipide, coronary atherosclerosis 
progression and clinical events in patients (pts) with metabolic syndrome (MSyn) were 
evaluated in the NIH-funded, a double-blinded, placebo-controlled, HDL Atherosclerosis 
Treatment Study (HATS). Method: Of 160 CAD pts enrolled and randomized to treatment 
(Rx) with SN(+) (daily dose 2-4 grn+10-20 rag) or placebo (SN(-)) in HATS, 77 (48%) had 
Msyn, which was defined as having any 3 of the following 4 criteria: (1) tdglycerides >=50 
mg/dl; (2) HDLc <40 in men or <50 in women; (3) treated hypertension or blood pressure 
>=130/85 mmHg; and (4) fasting glucose >=110 mg/dl, The lipid responses to Rx, pri- 
mary QCA endpoint (mean change in % stenosis) and clinical endpoint (CAD death, MI, 
stroke, or revascularization) were compared between SN(+) and SN(-) in both pts with 
and without MSyn. Results: See table. *: vs baseline p<0.001, 1": vs SN(-), p<O.05. ~:: vs 
MSyn(-) p=0.02. Conclusions: Patients with MSyn have a significantly greater rate of 
CAD progression and a 2-fold higher frequency of clinical events than without, Treatment 
with SN effectively lowers total cholesterol, tdglycerides and LDLc, raises HDLc without 
significantly affecting fasting glucose and insulin levets, and reduces CAD progression by 
90% and cardiovascular events by 40% in patients with MSyn. These data suggest that 
patients with MSyn should be treated more aggressively and simvastatin plus niacin 
appear to be an effective thera W, 
N Total LDLc Tdglycaddss HDLc Glucose InsulinQCA %S Event n (% 
cholesterol Base/Rx Base/Rx Base/Base/Rx Base/ change of pts) 
Base/Rx Rx Rx (SD) 
SN(+)MSyn(+)32 203/148" 125/76" 251/176" 31/39" 115/118 30/37 0.4 6/34(18%) 
(4.0)? 
MSyn(-)41 195/138" 126/78" 206/128" 31/36" 97/106 23/27 0.1 1/46(2%)? 
(2.2)? 
SN(-) MSyn(+)37 197/192 116/109 258/271 32/33 109/109 24/26 4.1 13/43(30%) 
(5.9)$ 
MSyn(-) 36 191/187 130/121 153/165 32/34 92/100 20/24 1.4(2.9) 5/37(14%) 
1130-75 Impact  o f  P ravsetat in  on  Secondary  P revent ion  o f  
Coronary  Ar tery  Disease in Normol lp ldemlc  Pat ients:  
Five-Year Angiogrephical Follow-Up Results of 
Prospective Randomized Trial (PCS study) 
Tsutomu Nakaoawa. Tohru Kobeyeshi, Nobuhisa Awata, Johan H. Reiber, Shinichi Sato, 
Tomoko Kobayashi, ¥oshihiro Takeda, Osaka Medical Canter for Cancer and 
Cardiovascular Diseases, Osaka, Japan, Department of Radiology, Leiden University 
Medical Center, Leiden, The Netherlands. 
Background: Prevention of Coronary Sclerosis (PCS) Study was designed to evaluate 
the long-term angiographic effect of pravastatin on secondary prevention of progression 
of coronary artery disease (CAD). Methods: 329 patients with CAD were enroUed and 
classified into three groups due to serum total cholesterol level: Group1 (TC>=220 rag/ 
